Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Total 13F shares
-
4,717,310
-
Share change
-
+4,717,310
-
Total reported value
-
$85,197,000
-
Price per share
-
$18.06
-
Number of holders
-
21
-
Value change
-
+$85,197,000
-
Number of buys
-
21
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q2 2017
As of 30 Jun 2017,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,717,310 shares.
The largest 10 holders included
ProQuest Associates IV LLC, FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, HIGHLINE CAPITAL MANAGEMENT, L.P., Hillhouse Capital Management, Ltd., PERCEPTIVE ADVISORS LLC, JENNISON ASSOCIATES LLC, Wildcat Capital Management, LLC, MENORA MIVTACHIM HOLDINGS LTD., and Alyeska Investment Group, L.P..
This page lists
21
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.